RecruitingPhase 4NCT03933384
Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B
Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B: an Open Label, Randomized Controlled Trial
Sponsor
Taichung Veterans General Hospital
Enrollment
140 participants
Start Date
Aug 19, 2019
Study Type
INTERVENTIONAL
Conditions
Summary
To compare the efficacy and renal safety of tenofovir alafenamide (TAF) versus entecavir (ETV) in the chronic hepatitis B patients.
Eligibility
Min Age: 20 Years
Inclusion Criteria3
- Patients more than 20 years old
- Chronic hepatitis B patients
- Patients who were indicated for hepatitis B virus antiviral therapy
Exclusion Criteria8
- Decompensated liver disease (Child-Pugh B \&C)
- End stage renal disease (eGRF < 15 ml/min/1.73m2)
- Prior use of nucleot(s)ide analogues for chronic hepatitis B
- Prior use of interferon for chronic hepatitis B within six months
- Known history of human immunodeficiency virus or hepatitis C virus co-infection
- Concurrent other uncontrolled malignancy
- Women in pregnancy or lactation
- Cannot conform to the study protocol of this study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGTenofovir alafenamide
Tenofovir alafenamide 25mg/tab once daily
DRUGEntecavir
Entecavir 0.5mg/tab once daily
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03933384
Related Trials
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
NCT0712855036 locations
Evaluation of Patients With Liver Disease
NCT000019711 location
Screening for Hepatitis B, Hepatitis C and AIDS Viruses Using Dried Blood Spot
NCT0539042411 locations
National Liver Cancer Screening Trial
NCT0608423418 locations
hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis
NCT038264331 location